Access to Information Requests Completed – March 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

Completed Requests

For the month of March 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2009-00168	All documents submitted for or approved for clinical trials carried out in Canada for anti-cancer therapy involving the use of B7-1 (CD80), B7-2 (CD86), and/or interleukin 12 (IL-12) IN LEUKEMIA, LYMPHOMA, OR MYELOMA.	Disclosed in part	3
A-2009-00498	All interdepartmental communication of Health Canada and First Nations Inuit Health Branch related to the outbreak of H1N1 influenza on Manitoba reserves.	Disclosed in part	983
A-2009-01325	Information regarding the product Yasmin, DINs 02261723 and 02261731 by BAYER INC.	Disclosed in part	426
A-2010-00049	Health Canada consultations in April 2008, October 2008 and June 2009 regarding bisphenol A relating to Polycarbonate baby bottles.	Disclosed in part	2,073
A-2010-00273	All information regarding the Consumer Product Safety Directorate document dated March 8, 2010, headed Prohibition on the Advertisement, Sale of Import of Children’s Toys with Plant Seeds as Stuffing (Hazardous Product Act).	Disclosed in part	767
A-2010-00760	Any documentation relating to the use of CT (computed tomography) scans and overuse or CT scans and excessive radiation doses. (Jan 1, 2005 to Octr 14, 2010).	Disclosed in part	581
A-2010-01078	All documents exchanged with senior officials or the Minister and her officials concerning the European Union's desire to have increased drug patent regulatory protections for brand-name drugs as part of negotiations for a comprehensive economic and trade agreement (CETA) between Canada and the European Union. (Jan 1, 2010 to Jan 11, 2011).	Disclosed in part	270
A-2010-01318	Information regarding Air Bills between Airborne Energy and Health Canada. (Jan 1, 2010 to Dec 10, 2010).	Disclosed in part	413
A-2010-01450	Information regarding the medical device Cholesterol 123 test system, License number 27225 by PreMD Inc.	Disclosed in part	26
A-2010-01493	Follow-up request to A-2010-00953 which produced the summary of the first part of the radon survey. Documents that were used to prepare that survey that were generated within the first few months after it was completed.	Disclosed in part	1,853
A-2010-01511	Copies of all official documents or related files, concerning all persons assigned to a position via the Interchange Canada program. (Jan 1, 2008 to Mar 22, 2011).	Disclosed in part	9
A-2010-01538	Copy of the First Nations and Inuit Health policy on correspondence relating to outside agencies,  funded agencies or the public.	All disclosed	7
A-2010-01579	Copies of all medical device problem reports concerning tampons filed between 2008 and March 25, 2011, including the 10 filed about OB tampons & the 2 filed about tampax tampons.	Disclosed in part	643
A-2011-00016	All documents regarding the renewal of the health warning labels and inserts and/or other packaging and labelling requirements for tobacco products. (Jan 1, 2008 to Aug 5, 2010).	Disclosed in part	505
A-2011-00079	Information regarding the product ADVAIR DISKUS.	Disclosed in part	48
A-2011-00126	All documents relating to strategies for Health Canada Infoway, Inc. to produce corporate revenue streams from its investments.	Disclosed in part	170
A-2011-00140	Information regarding the product Tylosin Premix, DINs 00713481 and 00800422 by Bio Agri Mix LP.	Disclosed in part	1,148
A-2011-00175	AERs. Report numbers: 000157423, 000159042, 000165478, 000167338, 000168166, 000171715, 000171721, 000173248, 000173298 and 000173303.	Disclosed in part	14
A-2011-00181	AERs. Report numbers: 000184520, 000184525, 000185279, 000186001, 000186003, 000186338, 000186512, 000186643, 000187184 and 000187285.	Disclosed in part	46
A-2011-00189	AERs. Report numbers: 000200531, 000200686, 000200961, 000201297, 000201427, 000201491, 000201866, 000202166, 000202167 and 000202488.	Disclosed in part	33
A-2011-00204	Information regarding the product Tofacitinib by Pfizer Inc.	Disclosed in part	28
A-2011-00213	All briefing notes regarding supervised injection sites created between January 1, 2011 and May 17, 2011.	Disclosed in part	12
A-2011-00231	Information regarding the product ASA Daily Low Dose, DIN 02243101 by Pharmascience Inc.	Disclosed in part	191
A-2011-00239	All emails to and from Christina Zehaluk regarding discretionary food fortification. (Jan 1, 2010 to Jun 30, 2010).	Disclosed in part	253
A-2011-00294	Information regarding the product APO-LOVASTATIN - TAB 20MG, DIN 02220172 by APOTEX.	Disclosed in part	575
A-2011-00295	Information regarding the product APO-LOVASTATIN - TAB 40MG, DIN 02220180 by APOTEX.	Disclosed in part	575
A-2011-00297	All documentation relating to Oro Gold Cosmetics distributed by Mazal Enterprise. (Jan 1, 2006 to Jun 3, 2011).	Disclosed in part	123
A-2011-00302	All documents related to the Common Purchasing Alliance for Drugs/Pharmaceuticals and Medical Supplies/Devices. (May 1, 2010 to Jun 6, 2011).	Disclosed in part	18
A-2011-00328	All documents in MECS for the following files: 10-101896-212, 10-117778-625, 10-005015-863, 10-119029-893, 10-120432-211, 10-005591-93, 10-003344-321, 10-117322-341 and 10-118825-94.	Disclosed in part	266
A-2011-00423	AERs for the product Adalat XL. Report numbers: 000359118, 000359676 and 000360960.	Disclosed in part	7
A-2011-00488	Information regarding the medical device Integrity Coronary Stent System, License number 84904 by Medtronic Inc.	Disclosed in part	1,980
A-2011-00498	AERs for the product Celexa. Report numbers: 000359246, 000360403 and 000363340.	Disclosed in part	9
A-2011-00527	AERs for the product Tylenol. Report numbers: 000165871, 000165913, 000167338, 000168490, 000169571, 000169682, 000170219, 000172208, 000172937 and 000175089.	Disclosed in part	47
A-2011-00528	AERs for the product Tylenol. Report numbers: 000178908, 000181418, 000182239, 000185322, 000188761, 000188765, 000194830, 000197581, 000198225 and 000200606.	Disclosed in part	35
A-2011-00529	AERs for the product Tylenol. Report numbers: 000204522, 000205081, 000210604, 000211186, 000213488, 000213490, 000214359, 000215095, 000215815 and 000219400.	Disclosed in part	34
A-2011-00588	Provide a list of cigarette brands whose share of total cigarette sales exceeded 1 % of total Canadian cigarette sales. (Jan 1, 2010 to Jun 2011).	All disclosed	72
A-2011-00628	AERs for the product INTERFERON. Report numbers: 000302790, 000306048 and 000319810.	Disclosed in part	39
A-2011-00693	AERs. Report numbers: 000347412, 000357074, 000356962, 000346647, 000346786, 000346841, 000348098, 000348213, 000348214 and 000348215.	Disclosed in part	63
A-2011-00706	AERs. Report numbers: 000348216, 000348218, 000348219, 000348220, 000348316, 000350653, 000350654, 000354056, 00357960 and 000357971.	Disclosed in part	74
A-2011-00738	AERs. Report numbers: 000360477, 000364222, 000364223, 000364224, 000364225, 000364235, 000364236, 000364237, 000364238, 000364239, 000364240, 000364241, 000364242, 000364243, 000364244, 000364245, 000364246, 000364247, 000364248, 000364249, 000364250, 000364251, 000364252, 000364253, 000364255, 000364256, 000364259, 000364260, 000364796, 000365172 and 000359735.	Disclosed in part	129
A-2011-00768	List of test analysis reports and audits concerning radon. (Jan 1, 2008 to Sep 26, 2011).	All disclosed	9
A-2011-00770	All documents regarding BIO-alcamid class action. (Jan 1, 2005 to Oct 4, 2011).	Disclosed in part	249
A-2011-00807	Information regarding the product Glycéré Orme Rouge, NPN 80019072.	Disclosed in part	36
A-2011-00812	Information regarding the product Actonel, DIN 02316838.	Disclosed in part	405
A-2011-00906	All e-mails (including any and all attachments) to/from Chris Turner (Director General, Marketed Health Products Directorate) about energy drinks. (Apr 1, 2011 to Oct 15, 2011).	Disclosed in part	110
A-2011-00923	All question period material prepared for the Minister and/or Parliamentary Secretary. (Oct 16 2011 to Oct 31, 2011).	Disclosed in part	227
A-2011-00950	All analysis and comments on the Loblaw's Guiding Stars program.	Disclosed in part	31
A-2011-00958	Information regarding the product Nicotine Lozenges 2mg / Thrive Lozenges 2mg, NPN 80007464 by Novartis Consumer Health Canada Inc.	Disclosed in part	43
A-2011-00959	Information regarding the product Nicotine Lozenges 4mg / Thrive Lozenges 4mg, NPN 80007453 by Novartis Consumer Health Canada Inc.	Disclosed in part	40
A-2011-00973	All case files related to overpayments - non-insured health service providers, which resulted in a loss of $45,244, as referenced in the 2011-11 Public Accounts of Canada.	Disclosed in part	12
A-2011-00979	AERs for the product Epival. Report numbers: 000360723 and 000362769.	Disclosed in part	30
A-2011-01023	Information regarding the medical device QUARTET (QUADRIPOLAR S-CURVE FIXATION STEROID-ELUTING ENDOCARDIAL LEFT HEART LEAD), License number 87151 by St. Jude Medical, Cardiac Rhythm Management Division.	Disclosed in part	90
A-2011-01048	AERs. Report numbers: 000370015, 000359168, 000365369 and 000362317.	Disclosed in part	12
A-2011-01051	All documents concerning possible changes to health warnings and/or other packaging and labelling requirements for cigars other than little cigars as defined in section 2 of the Tobacco Act of Canada. (Feb 19, 2011 to Nov 17, 2011).	All disclosed	82
A-2011-01058	Information regarding the product Simponi by JANSSEN INC.	Disclosed in part	40
A-2011-01063	Information regarding the product Body Octane, NPN 80027372 by Vitazan Herbs and Vitamins Inc.	Disclosed in part	30
A-2011-01072	All comments received by Health Canada in response to the consultation document entitled 'Looking Forward: The Future of Federal Tobacco Control' (September 12, 2011).	Disclosed in part	848
A-2011-01080	Memos, reports, briefing notes and House cards produced by Health Canada concerning possible creation of a national organ donor registry. (May 1, 2011, to Dec 1, 2011).	Disclosed in part	12
A-2011-01113	Information regarding the medical device BAROTECH MONOPLACE HYPERBARIC OXYGEN CHAMBERS, License number 60118 by Barotech Inc.	Disclosed in part	29
A-2011-01136	All documents concerning the Quebec Red Cross Blood Donor Clinic entering into trusteeship in March 1995.	All disclosed	39
A-2011-01152	Any report(s) by inspectors from Health Canada’s Bureau of Biologics concerning the inspection of the Quebec Red Cross Blood Donor Clinic.	Disclosed in part	39
A-2011-01224	All 2011 documents on possible changes to Canada's Food Guide.	Disclosed in part	141
A-2011-01247	All documentation pertaining to the Consumer Product Recall of the 'Tosca' Gel Firebowl dated October 18, 2011 as well as information pertaining what prompted this recall. (Jul 30, 2011 to Dec 15, 2011).	Disclosed in part	114
A-2011-01260	All documents supporting the following statement made by the Deputy Minister to a Teleconference of Federal/Provincial/Territorial Deputy Ministers of Health on August 19, 2010: The Tobacco Liaison Committee was updated on the tobacco product labelling and the quitline initiative last week. The tobacco control environment has shifted. Contraband tobacco, which bypasses regulatory requirements such as labelling, is currently the most pressing concern for regulators, non-governmental organizations (NGOs), retailers, law enforcement agencies and the tobacco industry. Federally, a Task Force on Illicit Tobacco Products has been formed and there have been recent investments in law enforcement, Canada Border Services Agency and Canada Revenue Agency to combat this issue.	Disclosed in part	13
A-2011-01321	Any contracts related to event planning services such as: conferences, conventions, Galas, Appreciation Events, Meetings, Lectures, Parties, Staff Appreciations Events, Receptions, Annual General Meetings, Campaigns, Trade Shows, Team Building Workshops, Training Sessions, Promotional Events, Informational Sessions, Training Seminars, Product Launches. (Jan 1, 2009 to Jan 12, 2012).	No records exist	0
A-2011-01360	All documents regarding compliance with the prohibition on direct/extra billing and user charges and private insurance in ss. 17, 18, 20 and 45 of the Medicare Protection Act. (Dec 7, 2006 to Jan 18, 2012).	Disclosed in part	65
A-2011-01410	The entire paid for by Health Canada by an external reviewer summarizing the scientific studies on the biological and health effects of electromagnetic fields published from 1998 onward.	Disclosed in part	217
A-2011-01452	All local purchase orders processed by this institution in the National Capital Region for the procurement of Temporary Help Services during the period of January 2012.	All disclosed	1
A-2011-01453	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of January 2012.	Disclosed in part	85
A-2011-01454	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during January 2012.	All disclosed	3
A-2011-01455	All call-ups and amendments issued under the terms of the TBIPS Standing Offer (EN578-055605) in the National Capital Region during the month of January 2012.	No records exist	0
A-2011-01497	All correspondence to any organization or individual inviting them to participate in, or making them aware of, the consultations conducted by Health Canada between September 12, 2011 and October 11, 2011 in respect of the consultation document entitled Looking Forward: The Future of Federal Tobacco Control.	Disclosed in part	13
A-2011-01502	AERs for the product Cipralex. Report numbers: 000373760, 000374107, 000374327 and 000380609.	Disclosed in part	9
A-2011-01503	AERs for the product Celexa. Report numbers: 000377518 and 000377684.	Disclosed in part	7
A-2011-01534	Information regarding the product Argent Colloïdal; Argent Colloïdal Nutri-Sélect, NPN 80022553 by Homeocan Inc.	Disclosed in part	30
A-2011-01547	All documents concerning the city or Toronto and Analyze-ERR, the software documentation tool which tracks and analyzes medication errors. (Jan 1, 2007 to Feb 16, 2012).	No records exist	0
A-2011-01553	List of Access to Information requests submitted to Health Canada by the media during the calendar year 2009.	Disclosed in part	50
A-2011-01554	List of Access to Information requests submitted to Health Canada by the media during the calendar year 2010.	All disclosed	50
A-2011-01555	List of Access to Information requests submitted to Health Canada by the media during the calendar year 2011.	All disclosed	56
A-2011-01557	All documents regarding the pesticide Turf Revolution Weedinator (Registration Number: 29918).	Disclosed in part	57
A-2011-01561	AERs for the product Synthroid. Report numbers: 000371793 and 000373038.	Disclosed in part	3
A-2011-01562	AERs for the product Adalat XL. Report numbers: 000378168 and 000379485.	Disclosed in part	3
A-2011-01564	AERs for the product Cipro. Report numbers: 000378077, 000378639, 000379021 and 000379697.	Disclosed in part	14
A-2011-01565	AER for the product Diane-35. Report number: 000380151.	Disclosed in part	1
A-2011-01567	AER for the product Mirena. Report number: 000378478.	Disclosed in part	2
A-2011-01568	AER for the product Nexavar. Report number 000379279.	Disclosed in part	1
A-2011-01569	AERs for the product Xarelto. Report numbers: 000378469, 000378752 and 000380608.	Disclosed in part	5
A-2011-01571	AERs for the product Yaz. Report numbers: 000378294, 000378793 and 000380007.	Disclosed in part	3
A-2011-01573	All documents indicating if kitchen utensils were withdrawn from the market or blocked at the borders. (Jan 1, 2009 to Feb 21, 2012).	Disclosed in part	16
A-2011-01578	AERs for the product Olmetec. Report numbers: 000375425 and 000375543.	Disclosed in part	2
A-2011-01580	All documents showing the types of medications and medical equipment that have been preserved or never used, including quantities and monetary values. (Jan 1, 2000 to Feb 23, 2012).	No records exist	0
A-2011-01581	AERs for the product Biaxin. Report numbers: 000372142, 000369349, 000366707, 000365577 and 000365983.	Disclosed in part	6
A-2011-01590	A listing of the Access to Information requests submitted to Health Canada. (Jan 1, 2012 to Jan 31, 2012).	Disclosed in part	9
A-2011-01593	Information regarding the product Trizivir by GlaxoSmithKline Shire Biochem.	No records exist	0
A-2011-01616	All internal information regarding the 2011-12 Cyclical Enforcement program to improve industry enforcement in order to ensure compliance with existing and proposed product safety obligations.	No records exist	0
A-2011-01621	Information regarding the average wait times for applications under the Marihuana Medical Access Regulations during the following fiscal years: 2008/2009, 2009/2010 and 2010/2011.	No records exist	0
A-2011-01622	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of February 2012.	Disclosed in part	74
A-2011-01623	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during February 2012.	All disclosed	2
A-2011-01642	Information regarding the medical device INTEGRITY CORONARY STENT SYSTEM, License number 84904.	All disclosed	80
A-2011-01643	Number of SAP releases for the following drug for the months of January and February 2012: Elotuzomab.	All disclosed	1
A-2011-01645	AERs. Report numbers: 000332698, 000334206 and 000373487.	Disclosed in part	3
A-2011-01647	Number of SAP releases for the following drug for the months of January and February 2012: Panobinostat.	No records exist	0
A-2011-01648	Number of SAP releases for the following drug for the months of January and February 2012: Vorinostat.	No records exist	0
A-2011-01649	Number of SAP releases for the following drug for the months of January and February 2012: Gemtuzumab.	All disclosed	1
A-2011-01650	Number of SAP releases for the following drug for the months of January and February 2012: Alisertib.	All disclosed	1
A-2011-01651	Number of SAP releases for the following drug for the month of February 2012: Treanda.	All disclosed	1
A-2011-01652	Number of SAP releases for the following drug for the month of February 2012: Targretin.	All disclosed	1
A-2011-01653	Number of SAP releases for the following drug for the month of February 2012: Dacogen.	All disclosed	1
A-2011-01654	Number of SAP releases for the following drug for the month of February 2012: Carfilzomib.	No records exist	0
A-2011-01655	Number of SAP releases for the following drug for the month of February 2012: Folotyn.	All disclosed	1
A-2011-01656	Number of SAP releases for the following drug for the month of February 2012: Zolinza.	No records exist	0
A-2011-01657	Number of SAP releases for the following drug for the month of February 2012: Afatinib.	All disclosed	1
A-2011-01658	Number of SAP releases for the following drug for the month of February 2012: Prochymal.	No records exist	0
A-2011-01659	Number of SAP releases for the following drug for the month of February 2012: Halaven.	All disclosed	1
A-2011-01660	Number of SAP releases for the following drug for the month of February 2012: Cabazitaxel.	No records exist	0
A-2011-01661	Number of SAP releases for the following drug for the month of February 2012: Belinostat.	All disclosed	1
A-2011-01662	Number of SAP releases for the following drug for the month of February 2012: Campath.	No records exist	0
A-2011-01663	Number of SAP releases for the following drug for the month of February 2012: Feraheme.	No records exist	0
A-2011-01664	Number of SAP releases for the following drug for the month of February 2012: Bendamustine.	All disclosed	1
A-2011-01665	Number of SAP releases for the following drug for the month of February 2012: Brentuximab.	All disclosed	1
A-2011-01674	AERs pertaining to maintenance concerns with defibrillators and issues that have arisen with routine maintenance or lack thereof. (Jan 1, 2007 to Feb 1, 2012)	All disclosed	251
A-2011-01708	AER for the product Androcur. Report number: 000380464.	Disclosed in part	2
A-2011-01711	AERs for the product Avelox. Report numbers: 000381786, 000381795, 000381799, 000382128, 000382341 and 000382941.	Disclosed in part	11
A-2011-01713	AERs for the product Cipro. Report numbers: 000380499, 000381582, 000382241 and 000382342.	Disclosed in part	4
A-2011-01716	AER for the product Xarelto. Report number: 000380243.	Disclosed in part	2
A-2011-01717	AERs for the product Yasmin. Report numbers: 000381270, 000382145 and 000382329.	Disclosed in part	3
A-2011-01719	AERs for the product Yaz. Report numbers: 000380244 and 000380660.	Disclosed in part	2
A-2011-01720	Information regarding the product CESAMET.	No records exist	0
A-2011-01730	AER. Report number: 000368808.	All disclosed	1
A-2011-01741	Information regarding the product QVAR, DINs 02242029 and 02242030.	Disclosed in part	1,417